Frontier Biotechnologies (hereinafter referred to as the company, stock code: 688221. SH) announces that the preclinical data of FB2001 (generic name: Bofutrelvir), was recently published at the international peer-reviewed journal "Antiviral Research". This report highlighted the results of in vitro and in vivo evaluation of FB2001 against SARS-CoV-2.

FB2001 has significant inhibitory effects on the main SARS-CoV-2 variants Alpha, Beta, Delta and Omicron, and the half maximal inhibitory concentration EC₅₀ for the currently popular Omicron is 0.042 μM. The combination of FB2001 and remdesivir has enhanced antiviral activity in vitro. Human serum had no significant effect on the antiviral activity of FB2001. FB2001 can significantly reduce the viral load and titer of SARS-CoV-2 in the lungs and brains of mice. Results shown that significant improvement of the pathological damage in the lungs and brains of mice. Based on the pharmacokinetic model, it is predicted that the trough concentration of FB2001 in human lung tissue is 2.5 μg/mL, which is about 132 times the EC50 value of the anti-Omicron virus strain. These results indicate that FB2001 has a higher drug concentration in the local virus target organs, and more beneficial to clinical treatment.

Reference：

https://www.sciencedirect.com/science/article/pii/S0166354222002194